Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Chambers

Showing results (21-30 of 92) with videos related to

Pageof 10
Sort By:
Health Affairs (Project Hope)|August 5, 2015
Private payers disagree with Medicare over medical device coverage about half the timeJames D Chambers, Matthew Chenoweth, Teja Thorat, et al.
Journal of Managed Care & Specialty Pharmacy|March 29, 2023
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverageAri D Panzer, Michael Ingham, Silas Martin, et al.
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Limited role of patient input in specialty drug coverage policiesBrittany D'Cruz, Jennifer S Graff, Ari D Panzer, et al.
Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Characterizing health plan evidence review practicesAri D Panzer, Daniel E Enright, Jen Graff, et al.
Medical Care|December 24, 2011
Factors predicting Medicare national coverage: an empirical analysisJames D Chambers, Stephen Morris, Peter J Neumann, et al.
Health Affairs (Project Hope)|August 9, 2017
Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional ProcessJames D Chambers, Teja Thorat, Colby L Wilkinson, et al.
The Milbank Quarterly|August 30, 2023
Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated ApprovalPeter J Neumann, Elliott Crummer, James D Chambers, et al.
Health Affairs (Project Hope)|December 8, 2011
Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implementPeter J Neumann, James D Chambers, Françoise Simon, et al.
Orphanet Journal of Rare Diseases|February 6, 2022
Patients' access to rare neuromuscular disease therapies varies across US private insurersNikoletta M Margaretos, Komal Bawa, Natalie J Engmann, et al.
Cancer Research Communications|December 1, 2025
Real-World Clinical Oncology Outcomes Associated With the Accelerated Approval PathwayTu My To, Stacey Kowal, James D Chambers, et al.
Pageof 10

Showing results (21-30 of 92) with videos related to

Sort By:
Pageof 10
Health Affairs (Project Hope)|August 5, 2015
Private payers disagree with Medicare over medical device coverage about half the timeJames D Chambers, Matthew Chenoweth, Teja Thorat, et al.
Journal of Managed Care & Specialty Pharmacy|March 29, 2023
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverageAri D Panzer, Michael Ingham, Silas Martin, et al.
Journal of Managed Care & Specialty Pharmacy|August 2, 2021
Limited role of patient input in specialty drug coverage policiesBrittany D'Cruz, Jennifer S Graff, Ari D Panzer, et al.
Journal of Managed Care & Specialty Pharmacy|August 24, 2022
Characterizing health plan evidence review practicesAri D Panzer, Daniel E Enright, Jen Graff, et al.
Medical Care|December 24, 2011
Factors predicting Medicare national coverage: an empirical analysisJames D Chambers, Stephen Morris, Peter J Neumann, et al.
Health Affairs (Project Hope)|August 9, 2017
Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional ProcessJames D Chambers, Teja Thorat, Colby L Wilkinson, et al.
The Milbank Quarterly|August 30, 2023
Improving Food and Drug Administration-Centers for Medicare and Medicaid Services Coordination for Drugs Granted Accelerated ApprovalPeter J Neumann, Elliott Crummer, James D Chambers, et al.
Health Affairs (Project Hope)|December 8, 2011
Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implementPeter J Neumann, James D Chambers, Françoise Simon, et al.
Orphanet Journal of Rare Diseases|February 6, 2022
Patients' access to rare neuromuscular disease therapies varies across US private insurersNikoletta M Margaretos, Komal Bawa, Natalie J Engmann, et al.
Cancer Research Communications|December 1, 2025
Real-World Clinical Oncology Outcomes Associated With the Accelerated Approval PathwayTu My To, Stacey Kowal, James D Chambers, et al.
Pageof 10